Immunocorrecting properties of GB-115 dipeptide

• Published in: Bulletin of experimental biology and medicine 2008-05, Vol.145 (5), p.610-613
• Main Authors: Shipaeva, E. V., Kovalenko, L. P., Khaidukov, S. V., Kolik, L. G., Gudasheva, T. A., Durnev, A. D., Seredenin, S. B.
• Format: Article
• Language: English
• Subjects: Animals; Antibody Formation - drug effects; Biomedical and Life Sciences; Biomedicine; CD4-CD8 Ratio; Cell Biology; Cyclophosphamide; Cyclophosphamide - toxicity; Dipeptides - administration & dosage; Dipeptides - pharmacology; Immune response (humoral); Immune system; Immunodeficiency; Immunologic Deficiency Syndromes - chemically induced; Immunologic Deficiency Syndromes - drug therapy; Immunologic Deficiency Syndromes - immunology; Immunologic Factors - administration & dosage; Immunologic Factors - pharmacology; Internal Medicine; Laboratory Medicine; Macrophages; Macrophages, Peritoneal - drug effects; Macrophages, Peritoneal - immunology; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred CBA; Pathology; Phagocytes; Phagocytosis - drug effects; Pharmacology and Toxicology; Rodents; Tryptophan
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-008-0153-z

We studied the effects of a new dipeptide with anxiolytic activity (GB-115, N-phenylhexanoyl-glycyl-L-tryptophan amide) on parameters of the immune in intact mice and in animals with secondary immunodeficiency caused by cyclophosphamide. GB-115 in doses of 0.1–10 mg/kg stimulated phagocytic activity of peritoneal macrophages and humoral immune response in intact mice. GB-115 exhibited immunocorrecting activity in animals with secondary immunodeficiency.